

# Michael C Milone

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3152407/publications.pdf>

Version: 2024-02-01

113  
papers

16,161  
citations

53660

45  
h-index

33814

99  
g-index

115  
all docs

115  
docs citations

115  
times ranked

17651  
citing authors

#	ARTICLE	IF	CITATIONS
1	Chimeric Antigen Receptorâ€“Modified T Cells for Acute Lymphoid Leukemia. <i>New England Journal of Medicine</i> , 2013, 368, 1509-1518.	13.9	3,021
2	CAR T cell immunotherapy for human cancer. <i>Science</i> , 2018, 359, 1361-1365.	6.0	1,968
3	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. <i>Science Translational Medicine</i> , 2015, 7, 303ra139.	5.8	1,402
4	Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In Vivo. <i>Molecular Therapy</i> , 2009, 17, 1453-1464.	3.7	988
5	Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells. <i>Immunity</i> , 2016, 44, 380-390.	6.6	811
6	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 3360-3365.	3.3	758
7	Clinical use of lentiviral vectors. <i>Leukemia</i> , 2018, 32, 1529-1541.	3.3	519
8	B cell maturation antigenâ€“specific CAR T cells are clinically active in multiple myeloma. <i>Journal of Clinical Investigation</i> , 2019, 129, 2210-2221.	3.9	513
9	Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. <i>Science</i> , 2016, 353, 179-184.	6.0	468
10	An introduction to chimeric antigen receptor (CAR) T cell immunotherapy for human cancer. <i>American Journal of Hematology</i> , 2019, 94, S3-S9.	2.0	340
11	Multifactorial T-cell Hypofunction That Is Reversible Can Limit the Efficacy of Chimeric Antigen Receptorâ€“Transduced Human T cells in Solid Tumors. <i>Clinical Cancer Research</i> , 2014, 20, 4262-4273.	3.2	339
12	Targeted inhibition of tumor-specific glutaminase diminishes cell-autonomous tumorigenesis. <i>Journal of Clinical Investigation</i> , 2015, 125, 2293-2306.	3.9	319
13	Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells. <i>Cancer Immunology Research</i> , 2015, 3, 356-367.	1.6	247
14	Engineering Artificial Antigen-presenting Cells to Express a Diverse Array of Co-stimulatory Molecules. <i>Molecular Therapy</i> , 2007, 15, 981-988.	3.7	236
15	Substrate Rigidity Regulates Human T Cell Activation and Proliferation. <i>Journal of Immunology</i> , 2012, 189, 1330-1339.	0.4	230
16	F-actin polymerization and retrograde flow drive sustained PLCÎ³1 signaling during T cell activation. <i>Journal of Cell Biology</i> , 2012, 197, 775-787.	2.3	203
17	High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model. <i>Cancer Immunology Research</i> , 2018, 6, 36-46.	1.6	192
18	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy. <i>Blood</i> , 2016, 128, 360-370.	0.6	190

#	ARTICLE	IF	CITATIONS
19	Reducing <i>Ex Vivo</i> Culture Improves the Antileukemic Activity of Chimeric Antigen Receptor (CAR) T Cells. <i>Cancer Immunology Research</i> , 2018, 6, 1100-1109.	1.6	189
20	Efficacy and Safety of Hydroxychloroquine vs Placebo for Pre-exposure SARS-CoV-2 Prophylaxis Among Health Care Workers. <i>JAMA Internal Medicine</i> , 2021, 181, 195.	2.6	168
21	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma. <i>Clinical Cancer Research</i> , 2016, 22, 2684-2696.	3.2	157
22	4-1BB and CD28 Signaling Plays a Synergistic Role in Redirecting Umbilical Cord Blood T Cells Against B-Cell Malignancies. <i>Human Gene Therapy</i> , 2010, 21, 75-86.	1.4	148
23	Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. <i>JCI Insight</i> , 2018, 3, .	2.3	140
24	T-cell phenotypes associated with effective CAR T-cell therapy in postinduction vs relapsed multiple myeloma. <i>Blood Advances</i> , 2019, 3, 2812-2815.	2.5	133
25	Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. <i>Blood</i> , 2004, 105, 994-996.	0.6	132
26	Sleeping Beauty Transposon-mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies. <i>Molecular Therapy</i> , 2008, 16, 580-589.	3.7	130
27	Tat-Functionalized Near-Infrared Emissive Polymersomes for Dendritic Cell Labeling. <i>Bioconjugate Chemistry</i> , 2007, 18, 31-40.	1.8	128
28	The CPT1a inhibitor, etomoxir induces severe oxidative stress at commonly used concentrations. <i>Scientific Reports</i> , 2018, 8, 6289.	1.6	119
29	4-1BB costimulation promotes CAR T cell survival through noncanonical NF- $\kappa$ B signaling. <i>Science Signaling</i> , 2020, 13, .	1.6	115
30	Rapid manufacturing of non-activated potent CAR T cells. <i>Nature Biomedical Engineering</i> , 2022, 6, 118-128.	11.6	92
31	Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors. <i>Cancer Immunology Research</i> , 2015, 3, 815-826.	1.6	87
32	Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. <i>Journal of Clinical Investigation</i> , 2016, 126, 2642-2660.	3.9	81
33	The Pharmacology of T Cell Therapies. <i>Molecular Therapy - Methods and Clinical Development</i> , 2018, 8, 210-221.	1.8	78
34	Therapeutic Drug Monitoring of Mycophenolic Acid. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2007, 2, 1062-1072.	2.2	74
35	Imaging CAR T Cell Trafficking with eDHFR as a PET Reporter Gene. <i>Molecular Therapy</i> , 2020, 28, 42-51.	3.7	70
36	Laboratory Testing for Prescription Opioids. <i>Journal of Medical Toxicology</i> , 2012, 8, 408-416.	0.8	66

#	ARTICLE	IF	CITATIONS
37	Antigen-specific B cell depletion for precision therapy of mucosal pemphigus vulgaris. <i>Journal of Clinical Investigation</i> , 2020, 130, 6317-6324.	3.9	66
38	A human orthogonal IL-2 and IL-2R $\beta$ system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia. <i>Science Translational Medicine</i> , 2021, 13, eabg6986.	5.8	64
39	Results of ASERTAA, a Randomized Prospective Crossover Pharmacogenetic Study of Immediate-Release Versus Extended-Release Tacrolimus in African American Kidney Transplant Recipients. <i>American Journal of Kidney Diseases</i> , 2018, 71, 315-326.	2.1	62
40	Pre-clinical validation of B cell maturation antigen (BCMA) as a target for T cell immunotherapy of multiple myeloma. <i>Oncotarget</i> , 2018, 9, 25764-25780.	0.8	61
41	Engineering-enhanced CAR T cells for improved cancer therapy. <i>Nature Cancer</i> , 2021, 2, 780-793.	5.7	60
42	Genetic engineering of T cells for adoptive immunotherapy. <i>Immunologic Research</i> , 2008, 42, 166-181.	1.3	59
43	Improving T Cell Expansion with a Soft Touch. <i>Nano Letters</i> , 2017, 17, 821-826.	4.5	59
44	$\beta$ c-Signaling Cytokines Induce a Regulatory T Cell Phenotype in Malignant CD4+ T Lymphocytes. <i>Journal of Immunology</i> , 2008, 181, 2506-2512.	0.4	56
45	B-Cell Maturation Antigen (BCMA)-Specific Chimeric Antigen Receptor T Cells (CART-BCMA) for Multiple Myeloma (MM): Initial Safety and Efficacy from a Phase I Study. <i>Blood</i> , 2016, 128, 1147-1147.	0.6	56
46	Itacitinib (INC039110), a JAK1 Inhibitor, Reduces Cytokines Associated with Cytokine Release Syndrome Induced by CAR T-cell Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 6299-6309.	3.2	49
47	Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo. <i>Molecular Therapy</i> , 2020, 28, 1600-1613.	3.7	45
48	High-Throughput Mechanobiology Screening Platform Using Micro- and Nanotopography. <i>Nano Letters</i> , 2016, 16, 2198-2204.	4.5	42
49	Cross Talk between CD3 and CD28 Is Spatially Modulated by Protein Lateral Mobility. <i>Molecular and Cellular Biology</i> , 2014, 34, 955-964.	1.1	40
50	Functional deficiencies in two distinct interferon $\gamma$ -producing cell populations in peripheral blood mononuclear cells from human immunodeficiency virus seropositive patients. <i>Journal of Leukocyte Biology</i> , 1995, 57, 214-220.	1.5	39
51	Enhancing Chimeric Antigen Receptor T Cell Anti-tumor Function through Advanced Media Design. <i>Molecular Therapy - Methods and Clinical Development</i> , 2020, 18, 595-606.	1.8	39
52	Debulking SARS-CoV-2 in saliva using angiotensin converting enzyme 2 in chewing gum to decrease oral virus transmission and infection. <i>Molecular Therapy</i> , 2022, 30, 1966-1978.	3.7	39
53	Posterior Reversible Encephalopathy Syndrome (PRES) after Infusion of Anti-Bcma CAR T Cells (CART-BCMA) for Multiple Myeloma: Successful Treatment with Cyclophosphamide. <i>Blood</i> , 2016, 128, 5702-5702.	0.6	31
54	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. <i>Blood</i> , 2016, 128, 974-974.	0.6	28

#	ARTICLE	IF	CITATIONS
55	Methotrexate Clearance by High-Flux Hemodialysis and Peritoneal Dialysis: A Case Report. <i>American Journal of Kidney Diseases</i> , 2009, 53, 871-874.	2.1	25
56	Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. <i>Nature Cancer</i> , 2022, 3, 808-820.	5.7	21
57	Adoptive T cell immunotherapy for medullary thyroid carcinoma targeting GDNF family receptor alpha 4. <i>Molecular Therapy - Oncolytics</i> , 2021, 20, 387-398.	2.0	20
58	Lack of TNF $\alpha$ expression protects anaplastic lymphoma kinase-positive T-cell lymphoma (ALK+ TCL) cells from apoptosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 15843-15848.	3.3	19
59	Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma. <i>Blood</i> , 2018, 132, 1886-1886.	0.6	19
60	Enhanced Function of Redirected Human T Cells Expressing Linker for Activation of T Cells That Is Resistant to Ubiquitylation. <i>Human Gene Therapy</i> , 2013, 24, 27-37.	1.4	18
61	False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy. <i>Blood</i> , 2018, 131, 2596-2598.	0.6	18
62	Eltrombopag and Serum of a Different Hue. <i>Archives of Pathology and Laboratory Medicine</i> , 2013, 137, 1175-1175.	1.2	17
63	The Safety of Bridging Radiation with Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma. <i>Clinical Cancer Research</i> , 2021, 27, 6580-6590.	3.2	15
64	Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors. <i>Blood</i> , 2019, 134, 622-622.	0.6	15
65	Neurotoxicity Associated with a High-Affinity GD2 CAR $\alpha$ Response. <i>Cancer Immunology Research</i> , 2018, 6, 496-497.	1.6	14
66	High-Affinity Chimeric Antigen Receptor With Cross-Reactive scFv to Clinically Relevant EGFR Oncogenic Isoforms. <i>Frontiers in Oncology</i> , 2021, 11, 664236.	1.3	14
67	PD-1 Inhibitor Combinations As Salvage Therapy for Relapsed/Refractory Multiple Myeloma (MM) Patients Progressing after Bcma-Directed CAR T Cells. <i>Blood</i> , 2018, 132, 1973-1973.	0.6	13
68	Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma. <i>Blood</i> , 2019, 134, 1863-1863.	0.6	13
69	Hyponatremia Associated With Levamisole-Adulterated Cocaine Use in Emergency Department Patients. <i>Annals of Emergency Medicine</i> , 2012, 60, 94-96.	0.3	12
70	Adoptive immunotherapy: New ways to skin the cat?. <i>Clinical Immunology</i> , 2005, 117, 101-103.	1.4	11
71	Predictors of T Cell Expansion and Clinical Responses Following B-Cell Maturation Antigen-Specific Chimeric Antigen Receptor T Cell Therapy (CART-BCMA) for Relapsed/Refractory Multiple Myeloma (MM). <i>Blood</i> , 2018, 132, 1974-1974.	0.6	10
72	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. <i>Blood</i> , 2012, 120, 717-717.	0.6	10

#	ARTICLE	IF	CITATIONS
73	Investigative and clinical applications of synthetic immune synapses. <i>Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology</i> , 2013, 5, 75-85.	3.3	9
74	Stable HLA antibodies following sustained CD19+ cell depletion implicate a long-lived plasma cell source. <i>Blood Advances</i> , 2020, 4, 4292-4295.	2.5	9
75	Prophylactic Itacitinib (INCB039110) for the Prevention of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cells (CAR-T-cells) Therapy. <i>Blood</i> , 2019, 134, 1934-1934.	0.6	9
76	Repair of Tibial Plateau Fracture (Schatzker II). <i>JBJS Essential Surgical Techniques</i> , 2019, 9, e25.	0.3	8
77	Recovery of humoral immunity in patients with durable complete responses following chimeric antigen receptor modified t cells directed against CD19 (CTL019).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7564-7564.	0.8	8
78	Increased risk of citrate reactions in patients with multiple myeloma during peripheral blood stem cell leukapheresis. <i>Journal of Clinical Apheresis</i> , 2010, 25, 188-194.	0.7	7
79	Pharmacology of Chimeric Antigen Receptor-Modified T Cells. <i>Annual Review of Pharmacology and Toxicology</i> , 2021, 61, 805-829.	4.2	7
80	CAR T-Cells Depend on the Coupling of NADH Oxidation with ATP Production. <i>Cells</i> , 2021, 10, 2334.	1.8	7
81	Enhancing CAR T function with the engineered secretion of C.Âperfringens neuraminidase. <i>Molecular Therapy</i> , 2022, 30, 1201-1214.	3.7	7
82	Trafficking and persistence of alloantigen-specific chimeric antigen receptor regulatory TÂcells in Cynomolgus macaque. <i>Cell Reports Medicine</i> , 2022, 3, 100614.	3.3	7
83	Performance of Two Fentanyl Immunoassays against a Liquid ChromatographyÂ Tandem Mass Spectrometry Method. <i>Journal of Analytical Toxicology</i> , 2021, 45, 117-123.	1.7	6
84	Bâcell maturation antigen chimeric antigen receptor Tâcell reâexpansion in a patient with myeloma following salvage programmed cell death protein 1 inhibitorâbased combination therapy. <i>British Journal of Haematology</i> , 2021, 193, 851-855.	1.2	6
85	Powered and controlled T-cell production. <i>Nature Biomedical Engineering</i> , 2018, 2, 148-150.	11.6	5
86	Multi-Site Evaluation of Immunoassays for Antipsychotic Drug Measurement in Clinical Samples. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 1541-1550.	0.6	5
87	Immunotherapy Using Chimeric Antigen Receptor-Engineered T Cells: A Novel Cellular Therapy with Important Implications for the Clinical Laboratory. <i>Clinical Chemistry</i> , 2019, 65, 519-529.	1.5	4
88	Evaluation of a Nanoparticle-Based Busulfan Immunoassay for Rapid Analysis on Routine Clinical Analyzers. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 766-771.	1.0	4
89	Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma. <i>Blood</i> , 2019, 134, 1909-1909.	0.6	4
90	Humoral Immunity and Plasma Cell Changes in Patients Responding to CD19-Specific Chimeric Antigen Receptor (CAR)-Modified T-Cell Adoptive Immunotherapy. <i>Blood</i> , 2014, 124, 1110-1110.	0.6	4

#	ARTICLE	IF	CITATIONS
91	A Biomarker for Concussion: The Good, the Bad, and the Unknown. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 170-182.	0.6	3
92	Testing the Specificity of Compounds Designed to Inhibit CPT1A in T Cells. <i>Methods in Molecular Biology</i> , 2020, 2097, 83-90.	0.4	2
93	Minimally Ex Vivo Manipulated Gene-Modified T Cells Display Enhanced Tumor Control. <i>Blood</i> , 2016, 128, 4549-4549.	0.6	2
94	Effect of a Variable Magnetic Field on Clinical Laboratory Testing. <i>Clinical Chemistry</i> , 2009, 55, 1249-1250.	1.5	1
95	Commentary. <i>Clinical Chemistry</i> , 2012, 58, 1635-1635.	1.5	1
96	Breaking the Therapeutic Drug Monitoring Logistics Barrier. <i>Clinical Chemistry</i> , 2014, 60, 1471-1472.	1.5	1
97	Studying Immunoreceptor Signaling in Human T Cells Using Electroporation of In Vitro Transcribed mRNA. <i>Methods in Molecular Biology</i> , 2017, 1584, 443-450.	0.4	1
98	Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy. <i>Journal of Visualized Experiments</i> , 2019, , .	0.2	1
99	Human Orthogonal IL-2/IL-2R $\beta$ As a Tunable Approach to Enhance CD19-Specific CAR-T Cell Antitumor Activity. <i>Blood</i> , 2020, 136, 48-48.	0.6	1
100	New Etiology Of Cocaine ???true??? Positive Drug Screen: Does South American Tea Really Contain Cocaine?. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 253-254.	1.0	0
101	Commentary. <i>Clinical Chemistry</i> , 2010, 56, 1795-1796.	1.5	0
102	Commentary. <i>Clinical Chemistry</i> , 2011, 57, 674-674.	1.5	0
103	516. Chimeric Antigen Receptors With Distinct Signaling Domains Can Reprogram T Cells. <i>Molecular Therapy</i> , 2015, 23, S206-S207.	3.7	0
104	21. Non-CD3-Based Chimeric Antigen Receptor (CARs) with Enhanced Anti-Tumor Activity in Solid Tumors. <i>Molecular Therapy</i> , 2015, 23, S10.	3.7	0
105	Commentary. <i>Clinical Chemistry</i> , 2019, 65, 1361-1361.	1.5	0
106	Signaling Domain of Chimeric Antigen Receptors Can Reprogram T Cells. <i>Blood</i> , 2014, 124, 551-551.	0.6	0
107	The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Engraftment and Antitumor Responses Against Mantle Cell Lymphoma. <i>Blood</i> , 2015, 126, 704-704.	0.6	0
108	Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality. <i>Blood</i> , 2015, 126, 147-147.	0.6	0

#	ARTICLE	IF	CITATIONS
109	Engraftment of Human MDS Samples in Xenotransplanted Mice Depends on Human Cytokines but Not Mesenchymal Stem Cells (MSC). <i>Blood</i> , 2016, 128, 1980-1980.	0.6	0
110	Optimized FVIII-Domain-Based Chimeric Antigen Receptors to Specifically Target FVIII Inhibitor-Producing B Cells in Hemophilia a. <i>Blood</i> , 2018, 132, 2196-2196.	0.6	0
111	Simple, 1-Day Manufacturing of Quiescent Chimeric Antigen Receptor T Cells for Adoptive Immunotherapy. <i>Blood</i> , 2019, 134, 4436-4436.	0.6	0
112	Perfecting CAR Engraftment to a Tee (Cell) through Characterization of Single Cell Transcriptome Product and Understanding Neurotoxicity. <i>Blood</i> , 2021, 138, 1707-1707.	0.6	0
113	Ontogeny of the Alloimmune Anti-Canine Factor VIII Inhibitor Response in Severe Hemophilia $\hat{t}$ Dogs. <i>Blood</i> , 2021, 138, 3173-3173.	0.6	0